Cell line · CVCL_1600
Papers68
1 to 20 of 68
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD47 promotes myeloma cell growth through JAK-STAT3/MYC signalling and is targetable by ruxolitinib. | Br J Haematol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. | Theranostics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. | Blood Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic potential of PRMT1 as a critical survival dependency target in multiple myeloma. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. | Blood Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. | PLoS Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1600/papers